Skip to main content
. 2019 Sep;8(5):2187–2191. doi: 10.21037/tcr.2019.08.26

Figure 1.

Figure 1

Clinical monitoring of the non-small cell lung cancer patients during TKI treatment. CT images during treatment are shown at different time points to monitor metastatic tumor size in the brain area and chest of two patients with GCC2-ALK fusion. (A) Ceritinib and alectinib treatment; (B) lorlatininb treatment; (C) crizotinib and X396 treatment. TKI, tyrosine kinase inhibitor.